Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2-I) are the most recently approved drugs for type 2 diabetes (T2D). Recent clinical trials of these compounds reported beneficial cardiovascular (CV) and renal outcomes. A major cause of vascular dysfunction and CV disease in diabetes is hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellanti, Francesco, Lo Buglio, Aurelio, Dobrakowski, Michał, Kasperczyk, Aleksandra, Kasperczyk, Sławomir, Aich, Palok, Singh, Shivaram P, Serviddio, Gaetano, Vendemiale, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331534/
https://www.ncbi.nlm.nih.gov/pubmed/36051336
http://dx.doi.org/10.3748/wjg.v28.i26.3243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331534/
https://www.ncbi.nlm.nih.gov/pubmed/36051336
http://dx.doi.org/10.3748/wjg.v28.i26.3243

Ejemplares similares